ArticleClinical kidney journal2025
Donor-derived PLA2R-positive membranous nephropathy after post-mortal kidney transplantation.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Donor-derived glomerular diseases after organ transplantation are rare and may be challenging to diagnose. We report two kidney transplant recipients from a deceased donor with previously undiagnosed phospholipase A2 receptor (PLA2R)-positive membranous nephropathy (MN). Recipient 1 experienced delayed graft function with gross albuminuria; biopsy showed PLA2R-positive MN. Recipient 2 had immediate graft function. In both patients anti-PLA2R sera were negative, while retrospective donor testing confirmed an anti-PLA2R titer, suggesting donor-derived idiopathic MN. Follow-up under standard immunosuppression showed improving creatinine and partial remission of albuminuria in Recipient 1, and stable function with modest, transient albuminuria in Recipient 2. Thus, kidneys from donors with MN can yield acceptable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.